Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Monster Beverage Corp (MNST) vs 10X Genomics Inc (TXG) Price & Performance

Monster Beverage CorpTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Monster Beverage Corp vs 10X Genomics Inc — how do they compare? Monster Beverage Corp trades at $45.7 (market cap $89.20B), while 10X Genomics Inc trades at $57.21 (market cap $7.61B). The key difference: Monster Beverage Corp is far larger — about 11.7× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals.

MNSTTXG
Market Cap
$89.20B$7.61B
Sector
Consumer StaplesHealth
52-Week High
$49.97$58.57
52-Week Low
$30.86$11.34
Enterprise Value
$87.49B$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Monster Beverage Corp

Monster Beverage (MNST) trades at $45.53, down 0.35% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, maintaining robust profit margins above 23%. Recent Q2 2026 results exceeded expectations with $0.60 EPS versus $0.59 expected, driven by international growth. The stock completed a 2-for-1 split on August 11, 2026.

MNST presents a mixed outlook with strong earnings momentum and international expansion offset by premium valuation concerns. The stock trades at 42.16x P/E, above sector averages, while analyst consensus targets $51.14 suggest 12% upside. Key risks include competitive pressures in energy drinks and valuation sensitivity to growth sustainability.

10X Genomics Inc

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Monster Beverage Corp

Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.

Read more on MNST

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG